7
International Grants Secured
₹47.1Cr
Total Capital Mobilised
7.2 mo
Median Time to First Capital
Contents
1.0 — Methodology and Scope03
2.0 — Track A: International Grant Recipients (5)04
2.1 — Portable Oral Cancer Detection Device04
2.2 — Patented Microbial Crop Yield Consortium06
2.3 — Modular Off-Grid Energy Pod08
2.4 — Agri-Waste Biodegradable Packaging10
2.5 — Ceramic Membrane Water Purification12
3.0 — Track B: Grant and Equity Recipients (2)14
3.1 — Verified Clinical Data Marketplace14
3.2 — Precision Fermentation Protein Platform17
4.0 — Track C: Equity-Only Recipients (3)20
4.1 — Satellite-Fusion Crop Disease Detection20
4.2 — Carbon Credit MRV Platform for MSMEs22
4.3 — Non-Invasive Glucose Monitoring Wearable24
5.0 — Cross-Portfolio Findings26
1.0 — Methodology and Scope
India produces a disproportionate share of the world's frontier science relative to its share of global early-stage venture capital. The gap is not a shortage of invention. Across the ten engagements reviewed in this report, every founding team held either a granted patent, a patent application, or peer-reviewed validation of their core technology prior to EzeSeed's engagement. What each lacked, in varying combination, was a defensible business model, a financial model an investor could underwrite, a regulatory pathway mapped to a specific approval class, a cap table that would survive institutional diligence, and — most consistently — a narrative constructed for the specific audience being asked to fund it.
This report documents ten such engagements, selected to represent the three capital pathways EzeSeed's service architecture is built to serve: international grant funding alone, a combined sequence of grant and equity capital, and equity-only venture financing. Companies are anonymised throughout. Sector classification, technology description, financial figures, regulatory pathway, and outcome data are presented as recorded in EzeSeed's engagement files. Each case follows a uniform structure: company profile, diagnostic findings at the point of engagement, the specific service interventions applied, and a before-and-after exhibit quantifying the change.
Readers should treat the per-case financial figures as engagement-specific and not as a guarantee of replicable outcome. Capital formation outcomes are a function of technology quality, team composition, market timing, and investor relationships in addition to advisory intervention. This report documents what was done and what followed; it does not claim sole causal attribution.
Section 2.1 · Engagement Reference EZ-MT-04
Portable, AI-Assisted Oral Cancer Detection Device
MedTech
Diagnostics
Patent Granted
Grant-Funded
| Origin | ICMR-affiliated cancer research centre; spin-out of two oncologists and one applied AI engineer |
| Founded | 2021 |
| Technology Readiness | TRL 4 at engagement — laboratory-validated, no clinical trial initiated |
| Core Innovation | Handheld optical coherence tomography probe with embedded AI lesion classifier; sensitivity 91%+ in controlled testing |
| Capital Outcome | ₹3.20 Crore — NIH SBIR Phase I (USD ~$150,000) and Wellcome Trust Innovations for Global Health award |
| Time to First Award | 7 months from engagement |
Technology and Clinical Rationale
Oral cancer is the single most prevalent cancer among Indian men by incidence, yet an estimated 70 percent of cases present at Stage III or later, reflecting the near-total absence of point-of-care screening infrastructure outside tertiary urban hospitals. The company's device is a handheld, battery-operated probe that performs optical coherence tomography on oral lesions, with an onboard classifier trained to flag pre-malignant and malignant tissue patterns. The underlying optical probe geometry and the AI classification method were both covered under a patent granted by the Indian Patent Office prior to EzeSeed's engagement.
Diagnostic Findings at Engagement
The patent was granted in India only; no freedom-to-operate analysis had been conducted against prior art registered in the United States or European Union, the two jurisdictions the founders intended to target for grant funding.
No CDSCO regulatory classification had been determined for the device. The founders could not state whether the product would be classified as a Class B, C, or D Software as a Medical Device under the 2017 Medical Device Rules.
A prior application to the U.S. National Institutes of Health under the SBIR programme had been submitted and rejected; the rejection letter cited absence of a commercialisation and translation plan, a standard requirement of the SBIR Phase I review criteria.
No cost or pricing model existed. The founders could state device manufacturing cost only as an estimate, with no breakdown between bill-of-materials cost, assembly cost, and target gross margin.
Market sizing in prior materials consisted of a single figure — approximately 100,000 new oral cancer cases annually in India — with no segmentation by care setting, procurement channel, or buyer type.
Exhibit 2.1.1Service Interventions Applied
| Service Line | Action Taken and Outcome |
|---|
| Regulatory Strategy | Determined CDSCO classification as Class C Software as a Medical Device under the Medical Device Rules 2017. Identified the FDA De Novo pathway as the relevant U.S. regulatory anchor required for SBIR eligibility, and prepared a written regulatory roadmap document submitted as an appendix to the grant application. |
| Grant Narrative — NIH SBIR | Rewrote the Specific Aims page in full. The original framing described the technology; the revised framing opened with the unmet clinical need and positioned the device against NIH's PA-21-262 medical device funding announcement, with an explicit commercialisation and translation section addressing the prior rejection reason directly. |
| Grant Narrative — Wellcome Trust | Positioned the application under the Innovations for Global Health funding strand. Quantified projected impact in disability-adjusted life years averted per 1,000 screenings, calculated against Wellcome's published cost-effectiveness benchmarks for early cancer detection interventions. |
| Financial Model Construction | Built bottom-up unit economics: bill-of-materials cost of ₹18,400 per unit; target average selling price of ₹85,000 for institutional B2B sale and ₹42,000 for government procurement channels. Modelled a three-year revenue scenario tied to projected deployment across Primary Health Centres under the National Health Mission infrastructure. |
| Intellectual Property Strategy | Commissioned a freedom-to-operate analysis covering the United States, European Union, and United Kingdom. Filed a PCT application to extend patent coverage into these jurisdictions, a contractual requirement under the NIH SBIR commercialisation clause. Two areas of claim overlap with prior art were identified and resolved through claim narrowing prior to filing. |
| Market Research | Re-sized the addressable market by procurement channel: 156,000 Primary Health Centres and Sub-Centres operating under the National Health Mission, 28,000 registered dental clinics, and 4,200 dedicated cancer treatment hospitals, each with distinct procurement cycles and pricing tolerance documented separately. |
Observation — Narrative Construction
The original NIH application opened: "We have developed an AI-powered device for oral cancer detection." The revised application opened: "Oral cancer kills more Indian men annually than cervical cancer kills Indian women, yet no portable, affordable, community-deployable screening device exists at scale anywhere in South Asia." The distinction between describing a product and quantifying the consequence of its absence is the most consistent pattern across the grant-funded engagements in this portfolio.
Exhibit 2.1.2Position at Engagement vs. Position at Award
| Dimension | At Engagement | At Award |
|---|
| Grant Applications | 2 submitted, both rejected | 4 submitted, 2 awarded |
| Regulatory Classification | Undetermined | CDSCO Class B SaMD; FDA De Novo pathway mapped |
| IP Jurisdiction Coverage | India only | PCT filed — India, United States, European Union, United Kingdom |
| Financial Model | None | Three-year P&L with channel-specific unit economics |
| Capital Secured | ₹0 | ₹3.20 Crore |
Service Lines Deployed
6 of 10
Pending Milestone
CDSCO submission, Q3 FY2026
Section 2.2 · Engagement Reference EZ-AG-07
Patented Microbial Consortium for Crop Yield Enhancement
AgriTech
Sustainability
Patent Granted
Grant-Funded
| Origin | ICAR research station, Punjab; founding scientist on institutional sabbatical, no business co-founder at engagement |
| Founded | 2020 |
| Core Innovation | Seven-strain microbial consortium — nitrogen-fixing bacteria, phosphate-solubilising fungi, mycorrhizal agents — as seed coating and soil drench |
| Trial Data | 23–31% yield increase across wheat, maize, soybean; 40% reduction in synthetic fertiliser requirement |
| Capital Outcome | ₹4.70 Crore — Bill & Melinda Gates Foundation Agricultural Development Programme and EU Horizon Europe Cluster 6 |
| Time to First Award | 9 months from engagement |
Diagnostic Findings at Engagement
The patent on the strain combination and formulation method was held in the name of the individual founding scientist, not by any registered legal entity — no company had been incorporated.
Trial results were published across three peer-reviewed agronomy journals but had never been repackaged for a commercial or grant-funding audience; the only existing document was the academic manuscript itself.
A prior application to the Department of Biotechnology's BioNEST programme had been rejected at the screening stage for an incomplete commercialisation plan.
No structured understanding existed of the Gates Foundation's Agricultural Development programme architecture, its funding priorities, or its application requirements.
The founder's stated go-to-market plan was direct sale to individual farmers — a channel strategy inconsistent with both the company's production capacity and the cost of farmer-level customer acquisition in rural India.
Exhibit 2.2.1Service Interventions Applied
| Service Line | Action Taken and Outcome |
|---|
| Business Structure | Incorporated a private limited company. Executed an intellectual property assignment deed transferring the patent from the individual scientist to the new corporate entity, with founder shareholding structured under a four-year vesting schedule to preserve future equity fundraising eligibility. |
| Grant Narrative — Gates Foundation | Aligned the application with the Foundation's Smallholder Productivity focus area. Quantified the farmer-level economic case at ₹4,200 in annual input cost saving per acre, benchmarked against the Foundation's published cost-effectiveness thresholds for agricultural interventions targeting sub-$2-per-day smallholders. |
| Grant Narrative — EU Horizon Europe | Positioned the application under Cluster 6 (Food, Bioeconomy, Natural Resources, Agriculture and Environment). Structured an EU-India research collaboration with a European soil microbiome research partner to satisfy Horizon's international collaboration eligibility criterion, and connected the application's stated impact directly to the EU Farm to Fork strategy's 50 percent pesticide reduction target. |
| Go-to-Market Strategy | Replaced the direct-to-farmer model with a B2B2C structure routed through State Agriculture Departments, Farmer Producer Organisations, and Krishi Vigyan Kendras. Mapped procurement budgets across 22 state agriculture departments with active bio-input procurement allocations totalling approximately ₹2,400 Crore annually. |
| Financial Model Construction | Modelled production scale-up from existing laboratory capacity of 200 kilograms per month to a 24-month target of 5 metric tons per month, with gross margin analysis at three distinct price points corresponding to government procurement, agri-input distributor, and premium direct-to-consumer organic farming channels. |
| Pitch Materials Reconstruction | Converted a 38-slide academic presentation built around journal citations into a 14-slide investor and grant-audience deck. Journal references were relocated to an appendix. The narrative opening was changed from microorganism taxonomy to documented farmer income impact. |
Observation — Intellectual Property Ownership
At engagement, the patent was held personally by the founding scientist rather than by a corporate entity — a structural condition common among researcher-led ventures spun out of public institutions. Both the Gates Foundation and EU Horizon Europe require that intellectual property generated or deployed under a funded project be held by a registered legal entity with a documented commercialisation pathway. Resolving this through incorporation and a formal assignment deed preceded all subsequent grant work and was completed within three weeks of engagement.
Exhibit 2.2.2Position at Engagement vs. Position at Award
| Dimension | At Engagement | At Award |
|---|
| Legal Entity Status | None — IP held by individual | Private limited company; IP assigned with vesting |
| Go-to-Market Channel | Direct-to-farmer | B2B2C via state agriculture departments and FPOs |
| Grant Applications | 1 rejected (DBT BioNEST) | 2 awarded (Gates Foundation, EU Horizon) |
| Capital Secured | ₹0 | ₹4.70 Crore |
Service Lines Deployed
6 of 10
Pending Milestone
State procurement pilot, FY2027
Section 2.3 · Engagement Reference EZ-CE-11
Modular Portable Clean Energy Pod for Off-Grid Rural Livelihoods
Clean Energy
Sustainability
Grant-Funded
| Origin | IIT-affiliated energy research group |
| Founded | 2022 |
| Core Innovation | Modular solar-charged battery pods — 100W, 500W, 1kW — with utility model registration on the daisy-chain coupling system |
| Target User | India's estimated 52 million informal-economy workers operating without reliable grid access |
| Capital Outcome | ₹2.80 Crore — USAID Development Innovation Ventures Stage 1 and Shell Foundation energy access portfolio |
| Time to First Award | 8 months from engagement |
Diagnostic Findings at Engagement
A functioning pilot with 47 users had been operating for several months but was internally described and treated as an experiment, with no structured collection of usage, income, or impact data.
No awareness existed of USAID's Development Innovation Ventures programme as an applicable grant pathway, despite a close fit with the programme's productive-use-of-energy funding priority.
The founding team had not resolved whether the commercial model would be outright hardware sale or a leasing structure, and no financial model existed for either approach.
The capitalisation table comprised four co-founders holding equal 25 percent stakes each — a structure identified during diligence as a standard institutional investment disqualifier given the absence of a clearly accountable operating lead.
Exhibit 2.3.1Service Interventions Applied
| Service Line | Action Taken and Outcome |
|---|
| Impact Measurement Design | Designed and retrofitted a measurement protocol across the existing 47-user pilot: daily energy consumption logs, pre- and post-deployment income comparison, hours of productive work enabled, and carbon dioxide emissions avoided relative to a kerosene baseline. This converted an undocumented product trial into an evidenced impact dataset suitable for grant submission. |
| Grant Narrative — USAID DIV | Built the Stage 1 application directly on the retrofitted pilot dataset, positioning the product as infrastructure connecting solar generation to productive economic use — the specific funding priority under USAID's energy access portfolio. |
| Grant Narrative — Shell Foundation | Constructed a rent-to-own financial model demonstrating a path to unit-level profitability within 18 months at 60 percent utilisation, addressing the Foundation's stated preference for commercially transitionable models over models requiring indefinite subsidy. |
| Business Model Determination | Modelled three revenue architectures — outright sale, pure leasing, and rent-to-own through a community charging hub — and selected rent-to-own based on combined net present value to the company and accessibility for the target user segment. |
| Founder Derisking and Cap Table Restructuring | Restructured the four-way equal split: two non-operating co-founders moved to advisory roles at 5 percent each; the two active operating founders retained 35 percent each under three-year vesting; the remaining 20 percent reserved for an employee stock option pool and future investors. |
| Regulatory Strategy | Identified the Bureau of Indian Standards certification requirement under IS 16046 for battery-based products, and mapped the Ministry of New and Renewable Energy registration pathway required for eligibility in state government off-grid solar procurement programmes. |
Exhibit 2.3.2Position at Engagement vs. Position at Award
| Dimension | At Engagement | At Award |
|---|
| Pilot Data | 47 users, no data collected | Full impact dataset across income, energy use, and emissions |
| Capitalisation Table | Four founders at equal 25% | Two operating founders at 35%, advisors at 5%, 20% reserved |
| Business Model | Undetermined between three options | Rent-to-own selected and modelled at three scale points |
| Capital Secured | ₹0 | ₹2.80 Crore |
Service Lines Deployed
6 of 10
Pending Milestone
1,000-pod deployment, Q4 FY2026
Section 2.4 · Engagement Reference EZ-SU-09
Agricultural Waste-Derived Biodegradable Packaging for EU Export
Sustainability
CleanTech
Patent Pending
Grant-Funded
| Origin | NIT chemistry and materials engineering department |
| Founded | 2021 |
| Core Innovation | Moulded fibre packaging from paddy straw and sugarcane bagasse, compostable in 90 days, mechanically benchmarked against expanded polystyrene |
| Cost Position | 30% lower production cost than virgin pulp-based alternatives |
| Capital Outcome | ₹3.60 Crore — EU ESPR Transitional Support mechanism and UKRI Global Challenges Research Fund |
| Time to First Award | 10 months from engagement |
Diagnostic Findings at Engagement
The founding team had attended two European trade fairs and received buyer interest, but could not progress conversations due to absence of product certification, a structured pricing sheet, or a minimum order quantity framework.
A patent application had been filed only with the Indian Patent Office; no PCT filing existed to protect the technology in the European and UK markets being targeted for commercialisation.
No working understanding existed of EU Ecodesign for Sustainable Products Regulation requirements, CE marking obligations, or the customs classification applicable to compostable packaging exports.
The revenue model assumed direct-to-brand sales with no understanding of the European Union's packaging distribution intermediary structure, which typically governs market access for non-EU suppliers at this scale.
Exhibit 2.4.1Service Interventions Applied
| Service Line | Action Taken and Outcome |
|---|
| EU Market Entry Strategy | Identified Germany and the Netherlands as priority markets based on ESG-linked procurement budget allocation. Restructured the entry route through EU-based sustainability-focused packaging distributors rather than direct brand sales, reducing the projected sales cycle from approximately 18 months to 4–6 months. |
| Grant Narrative — EU ESPR Fund | Positioned the application under the ESPR Transitional Support mechanism applicable to non-EU suppliers. Quantified that the product's 90-day compostability period exceeds the ESPR biodegradation requirement, and connected the agricultural waste reduction in India to a documented co-benefit for EU-measurable air quality, given paddy straw burning's contribution to cross-border particulate pollution. |
| Grant Narrative — UKRI GCRF | Aligned the application with the Global Challenges Research Fund's Sustainable Agriculture challenge area, and structured a formal UK-India collaboration with a UK academic institution to satisfy GCRF's joint research eligibility requirement. |
| Intellectual Property Strategy | Filed a PCT application covering EU and UK jurisdictions prior to grant submission, a contractual condition under UKRI's intellectual property ownership clause. One area of overlap with existing EU packaging material patents was identified and resolved through claim modification. |
| Certification Roadmap | Mapped the certification sequence required for EU market access: EN 13432 compostability standard, FSC Chain of Custody certification required for FMCG brand procurement eligibility, and BRC Packaging Standard, with a 12-month roadmap and testing laboratory contacts. |
| Commercial Framework | Built a three-tier pricing structure across spot, pilot-volume, and contract-volume purchasing, alongside minimum order quantity and lead-time documentation, and guidance on letter of credit and documents-against-payment trade finance instruments for first export transactions. |
Exhibit 2.4.2Position at Engagement vs. Position at Award
| Dimension | At Engagement | At Award |
|---|
| IP Jurisdiction Coverage | India only | PCT filed — India, EU, UK |
| EU Market Readiness | Trade fair contacts with no follow-through capability | Certification roadmap, pricing framework, distributor pipeline |
| Grant Applications | 1 technical proposal, rejected | 2 policy-aligned applications, both awarded |
| Capital Secured | ₹0 | ₹3.60 Crore |
Service Lines Deployed
6 of 10
Pending Milestone
First export shipment, EN 13432 certification
Section 2.5 · Engagement Reference EZ-CT-14
Low-Cost Ceramic Membrane for Decentralised Water Purification
CleanTech
Sustainability
Patent Granted
Grant-Funded
| Origin | NIT chemical engineering department |
| Founded | 2019 |
| Core Innovation | Clay-based ultrafiltration membrane, patented sintering process, 99.9% bacterial removal at ₹180 per unit vs ₹1,200 for polymer alternatives |
| Operating History | Five years founder-funded operation prior to engagement; revenue plateaued at ₹14 lakh annually for three consecutive years |
| Capital Outcome | ₹2.40 Crore — USAID Water Security for Health and Gates Foundation WASH-adjacent programme |
| Time to First Award | 11 months from engagement |
Diagnostic Findings at Engagement
Three government tender applications had been submitted and rejected at the technical bid stage, in each case for absence of Bureau of Indian Standards certification under IS 15498.
No awareness existed of USAID's Water Security programme or the Gates Foundation's WASH-adjacent funding streams as potential capital sources.
Investor and partner pitches framed the company narrowly as a lower-cost membrane component, without a story connecting the product to a system-level deployment model or a national policy framework.
No system integration partner had been identified; the company sold the membrane component in isolation rather than as part of a complete water purification system.
Exhibit 2.5.1Service Interventions Applied
| Service Line | Action Taken and Outcome |
|---|
| Narrative Restructuring | Repositioned the company from "lower-cost membrane supplier" to "India's first fully indigenous decentralised water purification solution addressing the last-mile quality gap in the Jal Jeevan Mission," connecting the product directly to the Government of India's ₹3.6 lakh crore rural piped water infrastructure programme. |
| Grant Narrative — USAID Water Security | Built the application around USAID's Water Security for Health strategic objective, quantifying disability-adjusted life years attributable to waterborne disease in target districts and positioning the membrane's cost profile as the removed barrier to community-level treatment adoption. |
| Grant Narrative — Gates Foundation | Constructed the economic case around comparative cost: ₹2 per person per month for water security via the membrane system versus ₹47 per person per month spent on bottled water by rural households without reliable purified access, aligned to the Foundation's water-adjacent funding mandate. |
| Regulatory Strategy | Mapped the Bureau of Indian Standards IS 15498 certification process for ceramic water filters and identified the fastest-turnaround NABL-accredited testing laboratory, producing a nine-month certification roadmap to unlock government tender eligibility — the channel that had been blocked for the prior five years. |
| Partnership Strategy | Identified and structured a supply agreement with a social enterprise operating community water kiosks in Rajasthan, repositioning the membrane as the core component of a complete system rather than a standalone component sale. |
| Financial Model Reconstruction | Rebuilt the revenue model from a single membrane unit sale at ₹180 to a system-level lifetime value model incorporating membrane replacement revenue on an 18-month cycle and service contract revenue, producing a per-kiosk lifetime value of ₹42,000 over five years. |
Exhibit 2.5.2Position at Engagement vs. Position at Award
| Dimension | At Engagement | At Award |
|---|
| Revenue Model | One-time component sale, ₹180 per unit | System lifetime value model, ₹42,000 per kiosk over five years |
| Regulatory Status | No BIS certification; blocked from government tenders | Certification roadmap mapped, testing initiated |
| Partnerships | None | System integration agreement executed |
| Capital Secured | ₹0 | ₹2.40 Crore |
Service Lines Deployed
6 of 10
Pending Milestone
BIS certification, first government tender bid
Section 3.1 · Engagement Reference EZ-HT-18
Verified Clinical Data Marketplace for Healthcare AI Training
HealthTech
MedTech
Grant + Equity
| Origin | Joint research initiative between AIIMS clinical faculty and an IIT computer science department |
| Founded | 2022 |
| Business Model | B2B SaaS — verified, anonymised clinical data licensed to healthcare AI laboratories, with a three-layer verification protocol commanding premium pricing |
| Capital Outcome | ₹9.40 Crore total — ₹2.20 Crore Wellcome Trust Data for Health grant and ₹7.20 Crore seed equity from a HealthTech-focused early-stage fund |
| Time to First Capital | 4 months to grant award; 11 months to equity close |
Diagnostic Findings at Engagement
The company described itself in all materials as "a data company," a positioning that triggers immediate investor concern around data ethics, governance liability, and long-term defensibility regardless of the underlying technical merit.
No architecture existed for compliance with the Digital Personal Data Protection Act 2023, a gap investors identified as a regulatory and legal liability during initial diligence conversations.
The revenue model consisted of per-dataset, one-time licensing transactions with no recurring revenue mechanism, producing financial unit economics resembling a data brokerage rather than a software business.
Two early-stage venture pitches had resulted in passes, both citing an unclear regulatory moat as the principal reason.
Applications to the Indian Council of Medical Research and the Department of Biotechnology had been rejected on the basis that the underlying activity was assessed as commercially, rather than research, motivated.
Exhibit 3.1.1Service Interventions Applied
| Service Line | Action Taken and Outcome |
|---|
| Business Model Restructuring | Redesigned the revenue architecture from one-time dataset licensing to annual subscription-based API access with tiered pricing, supplemented by data annotation and model validation services as additional recurring revenue lines. Gross margin improved from 38 percent under the original model to 71 percent under the restructured model. |
| Regulatory Architecture | Designed a Digital Personal Data Protection Act 2023 compliance framework comprising a consent management system, a data fiduciary registration roadmap, and an anonymisation protocol audit. This converted the company's regulatory exposure from a liability cited by investors into a documented compliance position that competitors had not yet replicated, functioning as a defensibility moat. |
| Investor Narrative Reframe | Repositioned the company from "data company" to "the compliance and quality verification infrastructure layer required by every Indian healthcare AI company." The reframed positioning secured two qualified investor meetings within 30 days of the revised narrative being deployed. |
| Grant Narrative — Wellcome Trust | Built the Data for Health application around a distinct public health rationale: that AI diagnostic models trained predominantly on Western patient data systematically underperform on Indian disease presentation patterns, and that verified, India-specific data infrastructure is a public good prerequisite for clinically reliable AI deployment in Indian healthcare settings. |
| Dual Pitch Deck Construction | Built separate documents for grant and venture audiences rather than a single hybrid pitch. The grant document emphasised public health impact exclusively; the venture document opened with market sizing (an estimated ₹9,400 Crore Indian healthcare AI market by 2028), competitive moat duration (an estimated 18-month replication lag for any new entrant), and the restructured ARR model. |
| Capitalisation Table Management | Structured the seed round using clean priced equity rather than convertible instruments, to avoid complicating subsequent institutional investor diligence. Established a 12 percent employee stock option pool and negotiated formal, clean equity terms for the AIIMS and IIT institutional stakes that had previously existed only as informal arrangements. |
Observation — Dual-Audience Narrative Construction
A single company frequently requires two structurally distinct narratives depending on whether the audience is a grant-making institution funding public goods or a venture investor underwriting a defensible, recurring-revenue business. A document constructed to satisfy both audiences typically satisfies neither. In this engagement, the grant application made no reference to annual recurring revenue; the venture pitch made no reference to disability-adjusted life years. Both were independently successful.
Exhibit 3.1.2Position at Engagement vs. Position at Capital Close
| Dimension | At Engagement | At Capital Close |
|---|
| Revenue Model | Per-dataset licensing, non-recurring | Annual subscription plus services, recurring |
| Gross Margin | 38% | 71% |
| Regulatory Position | DPDP non-compliant — cited as investor red flag | DPDP compliance framework documented — cited as investor moat |
| Venture Outcome | Two passes, "unclear regulatory moat" | Term sheet within 11 weeks of repositioning |
| Capital Secured | ₹0 | ₹9.40 Crore |
Time to Capital
4 mo. grant; 11 mo. equity
Service Lines Deployed
8 of 10
Pending Milestone
50 hospital supply contracts; Series A preparation
Section 3.2 · Engagement Reference EZ-FT-21
Precision Fermentation Platform for Sustainable Protein
Sustainability
FoodTech
Patent Pending
Grant + Equity
| Origin | Joint initiative between an IIT biotechnology department and a food science research group |
| Founded | 2021 |
| Core Innovation | Engineered yeast strain producing high-purity mycoprotein at 40% lower production cost, 70% lower land use, and 80% lower water use than animal-derived whey |
| Capital Outcome | ₹11.80 Crore total — ₹3.20 Crore EU Horizon Europe grant and ₹8.60 Crore Series Seed from a Singapore-based sustainable food fund |
| Time to First Capital | 6 months to equity close; 14 months to grant award |
Diagnostic Findings at Engagement
Four Indian venture capital pitches had each resulted in a pass, with reasons cited as regulatory risk associated with novel food approval and consumer adoption risk given limited Indian familiarity with precision fermentation products.
An initial EU Horizon Europe application had been rejected because it was not structured as a qualifying EU-India joint research collaboration, a procedural requirement for non-EU-led applications.
The existing financial model addressed only production volume, with no revenue model, customer segmentation, or pricing structure defined.
Competitive landscape materials referenced only Indian market players, omitting the broader global alternative protein investment context in which the company's relevant comparables and potential investors were actually situated.
Exhibit 3.2.1Service Interventions Applied
| Service Line | Action Taken and Outcome |
|---|
| Investor Geography Reorientation | Redirected venture targeting from Indian generalist funds, which had consistently passed on regulatory and adoption risk, to Singapore and European alternative-protein-focused funds with established sector risk appetite. A first qualified investor meeting was secured within six weeks of redirection. |
| Grant Narrative — EU Horizon Reapplication | Restructured the application as a formal EU-India joint project, identifying a leading European food science university as the EU-based academic partner, satisfying Horizon's international collaboration eligibility requirement under the Cluster 6 Food Systems topic. |
| Regulatory Strategy | Mapped a dual-track regulatory pathway — FSSAI Novel Food Product approval in India and EFSA Novel Food pre-submission in the European Union — and identified the Singapore Food Agency as the fastest available regulatory jurisdiction for first commercial launch, recommending a sequenced market entry beginning in Singapore. |
| Venture Pitch and Financial Model | Rebuilt the pitch narrative around a documented permanent cost-of-goods advantage relative to United States and European competitors and a completed EFSA pre-submission status. Constructed a financial model projecting ₹18 Crore in revenue within 36 months from business-to-business ingredient sales. |
| Go-to-Market Strategy | Rejected a direct-to-consumer launch route in favour of a business-to-business ingredient supply model targeting functional food categories including sports nutrition, infant formula, and clinical nutrition, removing the consumer behaviour change risk previously cited by Indian investors. |
| Founder Derisking | Identified a single-founder key-person dependency, as the lead scientist was the sole inventor and sole technical understander of the yeast engineering process. Recruited a second PhD-level bioprocess engineer as co-founder under a vesting structure, resolving a key-person risk previously cited by two prospective investors as a pass reason. |
Exhibit 3.2.2Position at Engagement vs. Position at Capital Close
| Dimension | At Engagement | At Capital Close |
|---|
| Investor Geography | India-only; four passes on regulatory risk | Singapore and EU funds; first meeting in six weeks |
| Go-to-Market Model | Direct-to-consumer | B2B ingredient supply to functional food categories |
| Key-Person Risk | Single founder, sole IP holder | Second co-founder added; knowledge transfer documented |
| Capital Secured | ₹0 | ₹11.80 Crore |
Time to Capital
6 mo. equity; 14 mo. grant
Service Lines Deployed
8 of 10
Pending Milestone
SFA approval; first B2B customer letter of intent
Section 4.1 · Engagement Reference EZ-AG-25
Satellite and Ground Sensor Fusion for Crop Disease Early Warning
AgriTech
Sustainability
Equity-Funded
| Origin | ICAR remote sensing research group |
| Founded | 2022 |
| Core Innovation | Synthetic aperture radar, multispectral satellite, and IoT ground sensor fusion; 87% disease detection accuracy at 72-hour advance notice |
| Pilot Scale | 340 farmers across two states; 34% average crop loss reduction documented |
| Capital Outcome | ₹6.80 Crore seed equity from an AgriTech-focused early-stage fund |
| Time to Term Sheet | 5 months from engagement |
Diagnostic Findings at Engagement
Pitch materials opened with technical model architecture description before establishing the underlying farmer problem, a sequencing identified during pitch rehearsal as causing audience disengagement within the first two minutes.
The pricing model charged farmers ₹500 per acre per season as the sole revenue channel, with no analysis conducted of farmer willingness to pay or of alternative payment structures such as insurance partnership or input-company bundling.
Market sizing referenced a 200 million farmer addressable population with no segmentation, prioritisation, or geographic specificity.
Pilot results from the 340-farmer deployment existed in raw form only — no structured testimonials, no before-and-after financial impact data per farmer, and no documented renewal or satisfaction metric.
Two prior venture conversations had expressed interest but stalled, with both investors specifically requesting evidence of farmer willingness to pay before proceeding.
Exhibit 4.1.1Service Interventions Applied
| Service Line | Action Taken and Outcome |
|---|
| Traction Documentation | Converted the 340-farmer pilot into a structured traction document quantifying an average of ₹8,400 in crop loss averted per acre, a ₹2,100 reduction in pesticide expenditure, and a 91 percent renewal rate, supported by anonymised farmer case studies and supporting photographic documentation. |
| Revenue Model Restructuring | Retained direct farmer pricing as a tertiary channel and constructed two primary business-to-business channels: an early-warning data feed licensed to crop insurance providers, projected to reduce their claims incidence by 18 to 22 percent, and a bundled advisory product sold through agricultural input companies. |
| Market Research and Segmentation | Replaced the undifferentiated 200 million farmer figure with a defined beachhead of 2.3 million soybean and cotton farmers across two states selected for the combination of high disease incidence and high existing crop insurance penetration, supported by a district-level deployment priority map. |
| Pitch Narrative Reconstruction | Revised the pitch opening to lead with the farmer-level problem and the 91 percent pilot renewal figure, deferring technical model architecture to a later section addressed only on investor request. |
| Financial Model Construction | Built a three-channel revenue model — insurance data licensing, agro-input advisory, and direct farmer subscription — with a bottom-up Year 1 revenue projection of ₹2.8 Crore derived from observed pilot unit economics rather than top-down market share assumption. |
| Investor Introductions | Facilitated introductions to three AgriTech-focused investors and arranged reference calls between the prospective lead investor and two of the 340 pilot farmers through an existing Farmer Producer Organisation relationship, a step the investor cited as decisive in the investment decision. |
Exhibit 4.1.2Position at Engagement vs. Position at Term Sheet
| Dimension | At Engagement | At Term Sheet |
|---|
| Revenue Channels | One — farmer subscription only | Three — insurance, agro-input, direct subscription |
| Market Sizing | 200 million farmers, undifferentiated | 2.3 million beachhead with district-level prioritisation |
| Venture Outcome | Two stalled conversations | Term sheet at third meeting post-reframing |
| Capital Secured | ₹0 | ₹6.80 Crore |
Time to Term Sheet
5 months
Service Lines Deployed
6 of 10
Pending Milestone
100,000-farmer scale; insurance API integration
Section 4.2 · Engagement Reference EZ-CT-29
Carbon Credit MRV and Issuance Platform for Indian MSMEs
CleanTech
Sustainability
Equity-Funded
| Origin | Co-founded by a carbon markets practitioner and an IIT electrical engineering researcher |
| Founded | 2023 |
| Core Innovation | Automated measurement, reporting, and verification platform reducing carbon credit issuance cost from ₹3.2 lakh to ₹18,000 per project |
| Target Segment | Indian MSME exporters facing EU Carbon Border Adjustment Mechanism compliance obligations |
| Capital Outcome | ₹5.20 Crore seed equity from a climate technology venture fund with co-investment from a climate impact fund |
| Time to Term Sheet | 6 months from engagement |
Diagnostic Findings at Engagement
No legal entity existed at engagement; the two founders were operating as an unincorporated partnership with no co-founder agreement.
Pitch materials relied on specialist carbon market terminology — referencing CORSIA, the Verified Carbon Standard, and Gold Standard certification schemes — without translation for a generalist venture investor audience.
No reference was made anywhere in the pitch to the EU Carbon Border Adjustment Mechanism, despite its direct relevance as a near-term compliance driver creating mandatory demand among the company's target customer segment.
The revenue model led with a ₹2,400 monthly SaaS subscription fee, with the considerably larger four-percent platform fee on carbon credit issuance value disclosed only on a later slide in the materials.
Market sizing referenced the global voluntary carbon market without India-specific segmentation or quantification of the addressable customer base.
Exhibit 4.2.1Service Interventions Applied
| Service Line | Action Taken and Outcome |
|---|
| Business Structure | Incorporated the company, executed a co-founder agreement with four-year cliff vesting, established a 15 percent employee stock option pool reserved prior to investor dilution, and assigned all measurement-reporting-verification algorithm intellectual property to the corporate entity. |
| Pitch Reframing Around Regulatory Driver | Repositioned the European Union's Carbon Border Adjustment Mechanism as the opening narrative element: a mid-sized Surat textile exporter facing an estimated ₹80 lakh annual carbon tariff cost from 2026 absent certified offsets, with the platform positioned as the affordable certification pathway. This converted the pitch from an abstract sustainability narrative into a concrete, quantified cost-avoidance product. |
| Revenue Model Restructuring | Moved the four-percent platform fee on issued carbon credit value to the primary revenue narrative position, demonstrating that at 500 customers issuing an average of 500 credits annually at ₹800 per credit, platform fee revenue of approximately ₹8 Crore annually substantially exceeds the SaaS subscription revenue of ₹1.44 Crore at the same customer base. |
| Market Research | Replaced the undifferentiated global voluntary carbon market reference with a specific addressable segment of 8,400 Indian exporters across textiles, steel, aluminium, and fertiliser facing mandatory EU carbon reporting obligations by 2026, of which an estimated 3 percent had any existing carbon credit strategy, yielding a quantified addressable platform-fee revenue opportunity of approximately ₹340 Crore. |
| Go-to-Market Strategy | Designed a distribution channel through India's Export Promotion Councils — specifically the Engineering Export Promotion Council, the Apparel Export Promotion Council, and the Indian Textile Accessories and Machinery Manufacturers' Association — as the single-access-point channel to the target customer base, securing a first formal partnership letter within eight weeks. |
| Investor Introductions | Facilitated introductions to two climate technology-focused investors. The CBAM-anchored narrative and the Export Promotion Council partnership letter were specifically cited by both investors as decisive credibility signals during the investment process. |
Exhibit 4.2.2Position at Engagement vs. Position at Term Sheet
| Dimension | At Engagement | At Term Sheet |
|---|
| Pitch Anchor | Carbon market terminology, opaque to generalist investors | EU CBAM cost-avoidance narrative, immediately legible |
| Revenue Emphasis | SaaS subscription (₹1.44 Cr at 500 customers) | Platform fee on issuance value (₹8 Cr at 500 customers) |
| Legal Structure | Unincorporated partnership | Private limited company, ESOP pool, IP assigned |
| Capital Secured | ₹0 | ₹5.20 Crore |
Time to Term Sheet
6 months
Service Lines Deployed
7 of 10
Pending Milestone
First 50 MSME customers; BEE registry integration
Section 4.3 · Engagement Reference EZ-HT-33
Non-Invasive Continuous Glucose Monitoring Wearable
HealthTech
MedTech
Patent Pending
Equity-Funded
| Origin | Joint initiative of an IIT biomedical engineering department and a hospital endocrinology unit |
| Founded | 2021 |
| Core Innovation | Wrist-worn near-infrared spectroscopy device with machine learning model trained on Indian patient data; Mean Absolute Relative Difference of 12.4% across 180-patient clinical testing |
| Target Segment | Type 2 diabetics on oral medication requiring between-meal trend monitoring, an underserved segment given the cost of invasive continuous glucose monitors |
| Capital Outcome | ₹8.40 Crore seed equity from a MedTech-focused venture fund with family office co-investment |
| Time to Term Sheet | 4 months from engagement |
Diagnostic Findings at Engagement
The company's competitive positioning materials compared the device directly to internationally established continuous glucose monitoring brands with full FDA approval, inviting investor scrutiny on regulatory risk the company was not yet positioned to address.
The stated regulatory plan was limited to a general intention to obtain CDSCO approval, with no defined device classification, predicate device identification, or submission timeline.
The go-to-market model was direct-to-consumer, a structure that produces high customer acquisition cost and no prescription-driven adoption mechanism in the diabetic device category.
Three prior venture pitches had each resulted in rejection, with all three citing United States Food and Drug Administration approval risk as the principal concern, despite the company's near-term commercial plan being limited to the Indian market.
No clinical advisory board existed — a standard diligence expectation among MedTech-focused investors evaluating clinical credibility.
Exhibit 4.3.1Service Interventions Applied
| Service Line | Action Taken and Outcome |
|---|
| Competitive Positioning Correction | Removed international continuous glucose monitoring brands from the competitive landscape and repositioned the device against the finger-prick glucometer — the actual Indian market incumbent, with a comparable monthly cost structure of approximately ₹2,160 — eliminating the unprompted FDA risk discussion that had recurred across prior investor meetings. |
| Regulatory Strategy | Defined the device's CDSCO classification as Class B Software as a Medical Device under the predicate category of glucose monitoring aids, and constructed an 18-month submission timeline, clarifying that United States regulatory approval was a Phase 2 international expansion consideration rather than a Phase 1 India launch requirement. |
| Go-to-Market Redesign | Replaced the direct-to-consumer channel with a business-to-business-to-consumer model routed through diabetologist clinical networks and existing diabetes management application platforms, reducing customer acquisition cost from an estimated ₹4,200 to ₹380 through prescription-driven adoption. |
| Clinical Advisory Board Formation | Facilitated recruitment of three key opinion leader endocrinologists from three distinct major Indian teaching hospitals as clinical advisors with nominal equity, a step that materially changed the tenor of subsequent investor conversations by signalling established clinical credibility. |
| Financial Model Construction | Built a three-stream revenue model combining one-time hardware sale at an average selling price of ₹4,800, a monthly data platform subscription at ₹299, and anonymised data licensing to pharmaceutical companies for drug-device clinical trial support, projecting Year 3 revenue of ₹22 Crore with gross margins of 34, 81, and 92 percent across the three streams respectively. |
| Investor Preparation and Coaching | Conducted structured pitch rehearsals incorporating anticipated investor objections regarding regulatory comparison and CDSCO planning, ensuring both objections were pre-empted within the first three slides of subsequent pitches rather than arising reactively during investor questioning. |
Exhibit 4.3.2Position at Engagement vs. Position at Term Sheet
| Dimension | At Engagement | At Term Sheet |
|---|
| Competitive Framing | Benchmarked against FDA-approved international brands | Benchmarked against finger-prick glucometer incumbent |
| Customer Acquisition Cost | Estimated ₹4,200 (direct-to-consumer) | Estimated ₹380 (prescription-driven, B2B2C) |
| Clinical Credibility | No clinical advisory board | Three key opinion leader endocrinologists engaged |
| Venture Outcome | Three rejections citing FDA risk | Term sheet at second meeting post-reframing |
| Capital Secured | ₹0 | ₹8.40 Crore |
Time to Term Sheet
4 months
Service Lines Deployed
8 of 10
Pending Milestone
CDSCO SaMD submission; diabetologist network pilot
5.0 — Cross-Portfolio Findings
10 of 10
Founding teams without a financial model at engagement
Every company reviewed in this portfolio had either no financial model or a production/technical model lacking any revenue or unit economics structure prior to EzeSeed's engagement.
7 of 10
Cases requiring cap table or legal entity correction
Including IP held by individuals rather than corporate entities, unincorporated partnerships, and founder equity splits inconsistent with institutional investment standards.
6 of 10
Cases where original go-to-market model was structurally unscalable
Most frequently a direct-to-consumer or direct-to-farmer model later replaced with a B2B or B2B2C channel structure.
5 of 10
Cases requiring international PCT patent filing prior to grant or investor submission
India-only patent protection was insufficient for grant bodies and investors requiring jurisdiction-specific IP coverage as a funding precondition.
Notes on Methodology and Disclosure
All company identities, founder names, and identifying institutional affiliations have been withheld or generalised in this report. Sector classification, core technology description, trial and pilot data, financial figures, and capital outcomes are presented as recorded in EzeSeed Global's internal engagement files at the time of writing. Where ranges or approximate figures are used, this reflects the precision of the underlying source data and is noted accordingly in the text. This report does not constitute investment advice, and capital outcomes described should not be construed as representative of expected returns for any prospective EzeSeed engagement, given that outcomes are dependent on technology quality, market conditions, team composition, and investor relationships in addition to advisory services rendered.